Loading
This study tests a PARP inhibitor; the registry reports that it is recruiting.
The registry lists NCT06568094 as recruiting, last updated 2026-09-17. Enrolment is 100 planned participants, an estimate. Interventions: HRS-5041 tablets, Abiraterone Acetate tablets（II）, Prednisone Acetate tablets, Docetaxel Injection, HRS-1167 tablets, SHR2554 tablets, HRS-6208 capsules, HRS-2189 Tablets. Primary measures include Recommended phase II dose (Phase Ib); Incidence and severity of adverse events (AE) (Phase Ib). No results are posted in the registry; this does not exclude separate publications.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares HRS-1167, Prednisone, Jiangsu Hengrui Pharmaceuticals, PARP.
Shares Prednisone, Jiangsu Hengrui Pharmaceuticals, Prostate cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/